HRS4R
Vull donar
Firma
JOAQUIM BOSCH-BARRERA
Posició
Investigador/a Consolidat - R3
Investigador/a Consolidat - R3

Projectes

Codi oficial: La Marató 201906-30 Data inici: 30/09/2020 Data fi: 29/09/2023 Investigador/a principal: JOAQUIM BOSCH BARRERA Organisme finançador: FUNDACIO LA MARATO TV3 Ajuda: 109,562.50 €
Codi oficial: Pfizer 2019 Joaquim Bosch Data inici: 05/07/2019 Data fi: 30/06/2023 Investigador/a principal: JOAQUIM BOSCH BARRERA Organisme finançador: PFIZER, S.L.U. Ajuda: 97,750 €
Codi oficial: 101057509 Data inici: 01/11/2022 Data fi: 31/10/2027 Investigador/a principal: RAMON BRUGADA TERRADELLAS Organisme finançador: EUROPEAN COMISSION Ajuda: 218,975 €

Publicacions

0

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism.

NATURE MEDICINE, 2022, 28, 752-765 dx.doi.org/10.1038/s41591-022-01749-8
0

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.

Bmc Cancer, 2022, 22, 732-732 dx.doi.org/10.1186/s12885-022-09830-8
0

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 dx.doi.org/10.3390/ijms23179986
0

Molecular Divergence upon EGFR -TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR -Sensitizing Mutation.

Cancers, 2022, 14 dx.doi.org/10.3390/cancers14184446
0

Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.

CLINICAL LUNG CANCER, 2022, 23 dx.doi.org/10.1016/j.cllc.2022.05.013

Romero A, Jantus-Lewintre E, García-Peláez B, Royuela A, Insa A, Cruz P, Collazo A, Pérez Altozano J, Vidal OJ, Diz P, Cobo M, Hernández B, Vázquez Estevez S, Benítez G, Guirado M, Majem M, Bernabé R, Ortega AL, Blasco A, Bosch-Barrera J, Jurado JM, García González J, Viteri S, Garcia Giron C, Massutí B, Lopez Martín A, Rodriguez-Festa A, Calabuig-Fariñas S, Molina-Vila MÁ, Provencio M

Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial.

MOLECULAR ONCOLOGY, 2021, 15, 43-56 dx.doi.org/10.1002/1878-0261.12832

Muñoz-Guardiola P, Casas J, Megías-Roda E, Solé S, Perez-Montoyo H, Yeste-Velasco M, Erazo T, Diéguez-Martínez N, Espinosa-Gil S, Muñoz-Pinedo C, Yoldi G, Abad JL, Segura MF, Moran T, Romeo M, Bosch-Barrera J, Oaknin A, Alfón J, Domènech C, Fabriàs G, Velasco G, Lizcano JM

The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells.

Autophagy, 2021, 17, 1-18 dx.doi.org/10.1080/15548627.2020.1761651

Bosch-Barrera J, Verdura S, Ruffinelli JC, Carcereny E, Sais E, Cuyàs E, Palmero R, Lopez-Bonet E, Hernández-Martínez A, Oliveras G, Buxó M, Izquierdo A, Morán T, Nadal E, Menendez JA

Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer.

Cancers, 2021, 13 dx.doi.org/10.3390/cancers13164168

Verdura S, Cuyàs E, Ruiz-Torres V, Micol V, Joven J, Bosch-Barrera J, Menendez JA

Lung Cancer Management with Silibinin: A Historical and Translational Perspective.

Pharmaceuticals, 2021, 14 dx.doi.org/10.3390/ph14060559

Niksic M, Redondo-Sanchez D, Chang YL, Rodriguez-Barranco M, Exposito-Hernandez J, Marcos-Gragera R, Oliva-Poch E, Bosch-Barrera J, Sanchez MJ, Luque-Fernandez MA

The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study.

Bmc Cancer, 2021, 21, 1048-1048 dx.doi.org/10.1186/s12885-021-08801-9

Propietat intel·lectual

Joaquim Bosch Barrera

MEANS FOR PREVENTING AND TREATING BRAIN METASTASIS

Número de publicació: EP20170382891 Data de publicació: 2019-06-26

Formulari de contacte

Coneix l’IDIBGI!

menu